Digital light processing (DLP) enables rapid prototyping of biocompatible contact lenses using silicone hydrogel formulations, with success dependent on optimizing photoinitiator concentration to balance cure kinetics and depth, combined with plasma-based post-print surface finishing to achieve optical clarity and reduce corneal irritation. Material selection of TMSPMA/HEMA/PEGDA systems and careful control of cure parameters are essential, though protein deposition remains a clinical consideration requiring multi-faceted material design approaches.
Successful rapid prototyping of biocompatible contact lenses via digital light processing requires careful selection of photopolymerizable materials that balance optical, mechanical, and biological requirements. The TMSPMA/HEMA/PEGDA silicone hydrogel system has emerged as a promising formulation specifically validated for DLP compatibility [1]. This material composition leverages the established biocompatibility of silicone hydrogels while incorporating hydrophilic monomers (HEMA) and polyethylene glycol derivatives (PEGDA) to achieve the crosslinked hydrophilic networks characteristic of advanced contact lens materials [3].
Silicone hydrogel systems represent the material class of choice because they achieve equilibrium water content between 20% and optimal levels for oxygen permeability, a critical parameter for corneal health [3]. The integration of hydrophobic silicone macromonomers with hydrophilic components creates a balanced network suitable for photopolymerization [5]. Beyond basic hydrogel chemistry, biomimetic engineering approaches are advancing the material science foundation for next-generation contact lenses, emphasizing not only oxygen transmissibility but also surface characteristics that minimize adverse biological interactions [2].
The photopolymerization process in DLP systems depends critically on photoinitiator (PI) chemistry and concentration optimization. Photoinitiators function by absorbing ultraviolet or visible light at specific wavelengths—commonly 365 nm—and decomposing into free radicals that initiate and propagate polymerization chains [6, 7]. However, achieving uniform three-dimensional cure throughout a contact lens geometry requires balancing competing effects of PI concentration.
Increase in photoinitiator concentration presents a fundamental trade-off in DLP processing [8, 9, 10]. Higher PI concentrations accelerate surface polymerization rates and increase light absorption, which initially deepens cure depth [9]. However, excessive PI concentration paradoxically reduces overall cure depth because the photoinitiator absorbs light preferentially at the surface, creating an optical barrier that prevents light penetration into deeper layers [8, 10]. Research demonstrates that cure depth exhibits a non-monotonic relationship with PI concentration, initially increasing then decreasing after reaching an optimal threshold [10]. For contact lens manufacturing, this optimization is particularly critical because the lens geometry demands uniform cure throughout its thickness while maintaining optical clarity.
UV LED curing systems, as employed in recent silicone hydrogel contact lens formulations, offer wavelength-specific advantages for controlling polymerization kinetics compared to traditional mercury lamps [5]. The specificity of LED excitation wavelengths enables more precise control over radical generation and polymerization kinetics, potentially improving uniformity across the lens cross-section.
Direct output from DLP printing inevitably produces surface irregularities, micro-roughness, and light-scattering defects that compromise optical clarity—a non-negotiable requirement for contact lenses. Post-manufacturing surface finishing therefore constitutes an essential process step for achieving clinical-grade optical performance.
Plasma-based treatments, particularly oxygen plasma processing, represent highly effective finishing methods for contact lens optics [11, 12]. Oxygen plasma etches the lens surface to create a more uniform finish while simultaneously removing surface irregularities, thereby reducing optical distortions [12]. Beyond optical improvement, plasma treatment modifies surface chemistry by increasing hydrophilicity and reducing surface roughness [11]. These changes benefit both optical function and biological compatibility by creating a more wettable surface that resists protein and lipid deposition.
Mechanical polishing methods provide complementary finishing capabilities, meticulously removing surface imperfections and producing smoother textures [15]. The combination of plasma treatment and mechanical polishing—potentially with controlled temperature gradients and optimized mold release approaches—enables production of defect-free, transparent optical surfaces comparable to conventionally manufactured contact lenses [14, 15].
Optical clarity and wettability represent necessary but insufficient conditions for clinical success. Corneal compatibility depends critically on minimizing adverse biological interactions, particularly protein adsorption and bacterial adhesion—phenomena that directly impact visual acuity, comfort, and safety [16, 18].
Protein deposition on hydrogel contact lenses is a complex, multi-factorial process mediated by protein characteristics (size, charge) and lens material properties [16, 17]. Protein deposits accumulate over wear cycles and create documented clinical consequences: diminished visual acuity, lens-induced dryness, discomfort, and lid-related inflammatory changes [18]. Material composition and surface finish directly influence protein adhesion rates; plasma-treated, high-hydrophilicity surfaces generally exhibit reduced protein accumulation compared to untreated or low-hydrophilicity materials [11, 16, 19].
Silicone hydrogel materials inherently exhibit superior protein resistance compared to conventional hydrogels due to their hydrophobic components, which provide some protection against protein adsorption [16, 17]. However, the TMSPMA/HEMA/PEGDA system's specific balance of hydrophobic and hydrophilic phases requires validation regarding protein deposition in clinical wear scenarios. The oxygen plasma treatment process, by increasing surface hydrophilicity, may create a trade-off between reduced protein adhesion and potential impacts on tear film stability—a consideration requiring further investigation in clinical studies.
Rapid prototyping of DLP-based contact lenses requires systematic integration of material selection, cure kinetics optimization, and post-print finishing. The workflow must begin with material formulations validated for DLP photopolymerization compatibility [1], proceed through careful optimization of photoinitiator concentration to ensure uniform three-dimensional cure [8, 10], and conclude with multi-stage surface finishing combining plasma treatment and mechanical polishing to achieve optical and biological standards [11, 12, 15].
The manufacturing advantages of DLP—speed, design flexibility, and reduced material waste compared to conventional molding—create compelling commercial potential. However, clinical-grade contact lens production demands that manufacturing efficiency never compromise optical clarity or biocompatibility. The silicone hydrogel TMSPMA/HEMA/PEGDA system combined with optimized cure kinetics and plasma-based finishing represents a promising path toward this goal, though ongoing clinical validation of protein deposition profiles remains essential for assured safety.
Rapid prototyping of biocompatible contact lenses via DLP represents an emerging manufacturing paradigm with substantial promise. Success requires simultaneous optimization across three interconnected domains: material chemistry emphasizing silicone hydrogel systems validated for photopolymerization, cure kinetics achieved through careful photoinitiator concentration control to balance polymerization rate and depth penetration, and post-print finishing using complementary plasma treatment and mechanical polishing to achieve optical clarity and enhanced surface hydrophilicity. While the core technology appears sound, extensive clinical validation of protein deposition and long-term corneal tolerance remains necessary before widespread adoption in commercial contact lens manufacturing.